Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jan-Mar;11(1):20-23.

Nonalcoholic fatty liver disease: epidemiology, pathogenesis and therapeutic implications

Craita Isabela Andronescu  1 , Monica Roxana Purcarea  2 , Petru Aurel Babes  3
Affiliations
Review

Nonalcoholic fatty liver disease: epidemiology, pathogenesis and therapeutic implications

Craita Isabela Andronescu et al. J Med Life. 2018 Jan-Mar.

Abstract

The increase of the prevalence of nonalcoholic fatty liver disease in the context of the explosive epidemy of obesity worldwide over the last decades and the emergence of new effective therapies for viral hepatitis has brought this entity to the forefront of hepatologist concerns. Today is a certainty that fatty liver can complicate with cirrhosis and hepatocellular carcinoma; moreover, nonalcoholic fatty liver disease is the main cause of cryptogenic cirrhosis and the second cause of liver transplantation. This review revises the epidemiology of the disease, brings forward some progress in pathogenesis and outlines the directions to be followed in nonalcoholic fatty liver disease prevention and therapy. Today, nonalcoholic fatty liver disease is considered to be the liver manifestation of metabolic syndome, with its same prevalence (20-30%). If the patients do not die through cardiovascular disease, it can lead to serious liver complications.

Keywords: Type 2 DM; central obesity; cryptogenic cirrhosis; hepatocellular carcinoma; insulin resistance.

PubMed Disclaimer

References

    1. Neuschwander-Tetri Brent A. Fatty Liver and Nonalcoholic steatohepatitis. In: Friedman Lawrence S., editor. Paul Martin Handbook of Liver Disease. 4th ed. Elsevier ; 2018.
    1. Sun John C, Burke Anne. The Clinician’s guide to liver disease. Slack Incorporated; 2006. Nonalcoholic Fatty Liver Disease.
    1. Bellentani Stefano. The epidemiology of nonalcoholic fatty liver disease. Liver international. 2017;37:81–84. - PubMed
    1. Diehl A.M, Day C. Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis. N Engl J Med . 23 Nov 2017;377(21) - PubMed
    1. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–2023. - PubMed

MeSH terms

LinkOut - more resources